3-(2,2,2-trimethylhydrazine)propionate has been researched along with orotic acid in 1 studies
| Studies (3-(2,2,2-trimethylhydrazine)propionate) | Trials (3-(2,2,2-trimethylhydrazine)propionate) | Recent Studies (post-2010) (3-(2,2,2-trimethylhydrazine)propionate) | Studies (orotic acid) | Trials (orotic acid) | Recent Studies (post-2010) (orotic acid) |
|---|---|---|---|---|---|
| 251 | 35 | 105 | 3,386 | 53 | 172 |
| Protein | Taxonomy | 3-(2,2,2-trimethylhydrazine)propionate (IC50) | orotic acid (IC50) |
|---|---|---|---|
| Solute carrier family 2, facilitated glucose transporter member 9 | Homo sapiens (human) | 1000 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cirule, H; Dambrova, M; Kalvinsh, I; Kuka, J; Liepinsh, E; Veveris, M; Vilskersts, R | 1 |
1 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and orotic acid
| Article | Year |
|---|---|
Myocardial infarct size-limiting and anti-arrhythmic effects of mildronate orotate in the rat heart.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Male; Methylhydrazines; Myocardial Infarction; Necrosis; Orotic Acid; Rats; Rats, Wistar; Reperfusion Injury | 2009 |